Horizon Therapeutics plc was a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases.[3] Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. Amgen acquired the company in October 2023.[4]
History
Horizon Therapeutics was founded in 2005 in Illinois focused on the development of Duexa, a formulation of ibuprofen combined with famotidine. Nitec Pharma AG was founded in Switzerland in 2004 as a spin-off from Merck KGaA.[5] In 2010, Horizon and Nitec merged to form a combined company Horizon Pharma Inc. to be led by Timothy Walbert to support the launch of Lodotra and Duexa.[6] Horizon IPOed in 2011 raising $49.5 million.[7]